Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare News Papua New Guinea.
Press releases published on August 11, 2025
New U.S. Politics Today Op-ed Says VOA Editorials Now Back Trump’s Political Agenda
EIN Presswire
·
August 11, 2025
WASHINGTON , DC, UNITED STATES, August 11, 2025 /EINPresswire.com/ -- For several decades, Voice of America has been a staple international multimedia broadcaster, known for promoting freedom and democracy in its reporting of news worldwide. But since …
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
GlobeNewswire
·
August 11, 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, …
Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
GlobeNewswire
·
August 11, 2025
Posts Positive Organic Growth and Adjusted EBITDA1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on …
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
GlobeNewswire
·
August 11, 2025
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC …
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
GlobeNewswire
·
August 11, 2025
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity …
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
GlobeNewswire
·
August 11, 2025
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related …
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients …
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 11, 2025
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of …
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
GlobeNewswire
·
August 11, 2025
Reiterating timelines for FDA submission in 2025 Transplant clinical trial has attracted leading transplant hospitals Booked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, …
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
GlobeNewswire
·
August 11, 2025
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results …
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 11, 2025
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C- …
Assertio Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, …
BioVie Inc. Announces Closing of $12 Million Public Offering
GlobeNewswire
·
August 11, 2025
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …
TELA Bio Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 11, 2025
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot …
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 11, 2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to Canada and the EU Company to host …
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 11, 2025
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on …